Bristol, AstraZeneca gain FDA nod for diabetes drug

01/8/2014 | Family Practice News

Bristol-Myers Squibb and AstraZeneca obtained federal approval for dapagliflozin to be used in the treatment of type 2 diabetes. The drug, a sodium-glucose co-transporter 2 inhibitor, will be marketed as Farxiga. The approval requires post-marketing studies by the manufacturer to determine risks related to the drug.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY